Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.97% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ALNY · Sep 30, 2025
ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001628280-25-047345General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
26.03% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
149.35% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
6.04% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
84.21% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
29.46% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
28.73% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
8.66% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History31 statesSelf-history eligible
Jun 30, 20218/9 normalizedLevel 3Sep 30, 20218/9 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/9 normalizedLevel 3Jun 30, 20228/9 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 1.85%
- Current
- 0.97%
- Delta
- -0.88%
- Previous
- 19.87%
- Current
- 26.03%
- Delta
- 6.16%
- Previous
- 17.26%
- Current
- 149.35%
- Delta
- 132.09%
- Previous
- 9.27%
- Current
- 6.04%
- Delta
- -3.23%
- Previous
- 81.64%
- Current
- 84.21%
- Delta
- 2.57%
- Previous
- -2.09%
- Current
- 29.46%
- Delta
- 31.56%
- Previous
- 41.83%
- Current
- 28.73%
- Delta
- -13.10%
- Previous
- 14.43%
- Current
- 8.66%
- Delta
- -5.77%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ALNY Fundamental State →Has State · ALNYLAM PHARMACEUTICALS, INC. →Transitioned To · ALNY Fundamental State →Transitioned To · ALNY CAPEX_INTENSITY_DECREASED →Transitioned To · ALNY CASH_GENERATION_INCREASED →Transitioned To · ALNY GROWTH_INCREASED →Transitioned To · ALNY INVENTORY_PRESSURE_DECREASED →Transitioned To · ALNY MARGIN_INCREASED →Transitioned To · ALNY PROFITABILITY_INCREASED →Transitioned To · ALNY R_AND_D_INTENSITY_DECREASED →Transitioned To · ALNY SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.